In an interview with Pharmalot, former FDA associate chief counsel Arnie Friede discusses the impact of last month’s $181 million Risperdal settlement on pharmaceuticals’ abilities to distribute journal articles that contain off-label information.
In an interview with Pharmalot, former FDA associate chief counsel Arnie Friede discusses the impact of last month’s $181 million Risperdal settlement on pharmaceuticals’ abilities to distribute journal articles that contain off-label information.
